濟川藥業(600566.SH)上半年淨利增31.93%至13.4億元 蒲地藍消炎口服液、小兒豉翹清熱顆粒等產品銷售收入持續增長
格隆匯8月13日丨濟川藥業(600566.SH)披露2023年半年度報吿,2023年1-6月,公司經營狀況良好,企業規模與實力穩步提升。
報吿期內,公司實現營業收入462,897.60萬元,較上年同期增長19.82%;歸屬於上市公司股東的淨利潤133,984.39萬元、歸屬於上市公司股東的扣除非經常性損益的淨利潤124,739.10萬元,分別比同期增長31.93%、38.47%,主要是因為報吿期內公司的蒲地藍消炎口服液、小兒豉翹清熱顆粒等產品銷售收入持續增長,同時公司銷售費用、管理費用增長得到有效控制所致。報吿期內,公司的扣除非經常性損益後的基本每股收益1.362元/股,較上年同期增長34.32%,主要是由於公司扣除非經常性損益後的淨利潤增長所致。報吿期內,公司經營活動產生的現金流量淨額219,853.05萬元,較上年同期增長50.03%,主要是由於銷售回籠增加所致。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.